Ocuphire Eyes Phase III Path For APX3330 After Mixed Trial Results

The diabetic retinopathy candidate failed on its Phase II primary endpoint, but showed efficacy on a key secondary endpoint that the company hopes to use as the Phase III primary outcome measure.